Objective: Patients with primary aldosteronism (PA) can present with high PTH levels and negative calcium balance, with some studies speculating that aldosterone could directly stimulate PTH secretion. Either adrenalectomy or mineralocorticoid receptor blockers could reduce PTH levels in patients with PA. The aim of this study was to assess the relationship between aldosterone levels and parathyroid hormone (PTH)-vitamin D-calcium axis in a cohort of patients with PA, compared with patients with nonsecreting adrenocortical tumors in conditions of vitamin D sufficiency. Methods: We enrolled a series of 243 patients retrospectively, of whom 66 had PA and 177 had nonsecreting adrenal tumors, and selected those with full mineral metabolism evaluation and 25(OH) vitamin D levels >20 ng/mL at the time of initial endocrine screening. The final cohort was composed of 26 patients with PA and 39 patients, used as controls, with nonsecreting adrenal tumors. The relationships between aldosterone, PTH levels, and biochemistries of mineral metabolism were assessed. Results: Aldosterone was positively associated with PTH levels (r = 0.260, P < .05) in the whole cohort and in the PA cohort alone (r = 0.450; P = .02). In the multivariate analysis, both aldosterone concentrations and urinary calcium excretion were significantly related to PTH levels, with no effect of 25(OH) vitamin D or other parameters of bone metabolism. Conclusion: PTH level is associated with aldosterone, probably independent of 25(OH) vitamin D levels and urinary calcium. Whether aldosterone interacts directly with the parathyroid glands remains to be established.

Association Between Aldosterone and Parathyroid Hormone Levels in Patients With Adrenocortical Tumors / Zavatta G.; Di Dalmazi G.; Altieri P.; Pelusi C.; Golfieri R.; Mosconi C.; Balacchi C.; Borghi C.; Cosentino E.R.; Di Cintio I.; Malandra J.; Pagotto U.; Vicennati V.. - In: ENDOCRINE PRACTICE. - ISSN 1530-891X. - ELETTRONICO. - 28:1(2022), pp. 90-95. [10.1016/j.eprac.2021.09.002]

Association Between Aldosterone and Parathyroid Hormone Levels in Patients With Adrenocortical Tumors

Zavatta G.
Primo
;
Di Dalmazi G.
Secondo
;
Altieri P.;Pelusi C.;Golfieri R.;Mosconi C.;Balacchi C.;Borghi C.;Cosentino E. R.;Di Cintio I.;Malandra J.;Pagotto U.
Penultimo
;
Vicennati V.
Ultimo
2022

Abstract

Objective: Patients with primary aldosteronism (PA) can present with high PTH levels and negative calcium balance, with some studies speculating that aldosterone could directly stimulate PTH secretion. Either adrenalectomy or mineralocorticoid receptor blockers could reduce PTH levels in patients with PA. The aim of this study was to assess the relationship between aldosterone levels and parathyroid hormone (PTH)-vitamin D-calcium axis in a cohort of patients with PA, compared with patients with nonsecreting adrenocortical tumors in conditions of vitamin D sufficiency. Methods: We enrolled a series of 243 patients retrospectively, of whom 66 had PA and 177 had nonsecreting adrenal tumors, and selected those with full mineral metabolism evaluation and 25(OH) vitamin D levels >20 ng/mL at the time of initial endocrine screening. The final cohort was composed of 26 patients with PA and 39 patients, used as controls, with nonsecreting adrenal tumors. The relationships between aldosterone, PTH levels, and biochemistries of mineral metabolism were assessed. Results: Aldosterone was positively associated with PTH levels (r = 0.260, P < .05) in the whole cohort and in the PA cohort alone (r = 0.450; P = .02). In the multivariate analysis, both aldosterone concentrations and urinary calcium excretion were significantly related to PTH levels, with no effect of 25(OH) vitamin D or other parameters of bone metabolism. Conclusion: PTH level is associated with aldosterone, probably independent of 25(OH) vitamin D levels and urinary calcium. Whether aldosterone interacts directly with the parathyroid glands remains to be established.
2022
Association Between Aldosterone and Parathyroid Hormone Levels in Patients With Adrenocortical Tumors / Zavatta G.; Di Dalmazi G.; Altieri P.; Pelusi C.; Golfieri R.; Mosconi C.; Balacchi C.; Borghi C.; Cosentino E.R.; Di Cintio I.; Malandra J.; Pagotto U.; Vicennati V.. - In: ENDOCRINE PRACTICE. - ISSN 1530-891X. - ELETTRONICO. - 28:1(2022), pp. 90-95. [10.1016/j.eprac.2021.09.002]
Zavatta G.; Di Dalmazi G.; Altieri P.; Pelusi C.; Golfieri R.; Mosconi C.; Balacchi C.; Borghi C.; Cosentino E.R.; Di Cintio I.; Malandra J.; Pagotto U.; Vicennati V.
File in questo prodotto:
Eventuali allegati, non sono esposti

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/854447
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 2
social impact